FY2025 Earnings Forecast for DYN Issued By Lifesci Capital

Dyne Therapeutics, Inc. (NASDAQ:DYN) – Equities research analysts at Lifesci Capital lifted their FY2025 earnings per share (EPS) estimates for shares of Dyne Therapeutics in a report issued on Wednesday, January 21st. Lifesci Capital analyst F. Brisebois now anticipates that the company will post earnings of ($3.53) per share for the year, up from their previous estimate of ($3.58). Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Dyne Therapeutics’ current full-year earnings is ($3.44) per share. Lifesci Capital also issued estimates for Dyne Therapeutics’ Q4 2025 earnings at ($0.81) EPS, Q1 2026 earnings at ($0.77) EPS, Q2 2026 earnings at ($0.77) EPS, Q3 2026 earnings at ($0.85) EPS, Q4 2026 earnings at ($0.85) EPS and FY2026 earnings at ($3.24) EPS.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.76) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.05.

DYN has been the topic of a number of other reports. Morgan Stanley lifted their price objective on Dyne Therapeutics from $46.00 to $50.00 and gave the stock an “overweight” rating in a research note on Monday, December 8th. Oppenheimer raised Dyne Therapeutics from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $11.00 to $40.00 in a research report on Wednesday, December 10th. TD Cowen reiterated a “buy” rating on shares of Dyne Therapeutics in a report on Monday, December 8th. Sanford C. Bernstein set a $23.00 price objective on Dyne Therapeutics in a research report on Tuesday, December 9th. Finally, Evercore ISI dropped their target price on shares of Dyne Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a research report on Monday, December 15th. Three analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $38.41.

Dyne Therapeutics Stock Performance

NASDAQ:DYN opened at $18.00 on Friday. The firm has a market capitalization of $2.57 billion, a PE ratio of -4.92 and a beta of 1.32. Dyne Therapeutics has a 1 year low of $6.36 and a 1 year high of $25.00. The company has a current ratio of 13.47, a quick ratio of 13.47 and a debt-to-equity ratio of 0.14. The firm’s fifty day simple moving average is $19.38 and its 200 day simple moving average is $15.72.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of DYN. Adage Capital Partners GP L.L.C. bought a new stake in Dyne Therapeutics in the second quarter valued at about $30,378,000. Marshall Wace LLP boosted its holdings in Dyne Therapeutics by 572.9% during the third quarter. Marshall Wace LLP now owns 3,013,377 shares of the company’s stock valued at $38,119,000 after purchasing an additional 2,565,570 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Dyne Therapeutics by 27.6% in the 3rd quarter. Vanguard Group Inc. now owns 9,760,414 shares of the company’s stock valued at $123,469,000 after purchasing an additional 2,109,257 shares during the period. Vestal Point Capital LP grew its stake in shares of Dyne Therapeutics by 281.4% in the 3rd quarter. Vestal Point Capital LP now owns 2,775,000 shares of the company’s stock valued at $35,104,000 after purchasing an additional 2,047,500 shares during the period. Finally, Deep Track Capital LP acquired a new position in shares of Dyne Therapeutics in the 3rd quarter worth approximately $25,300,000. 96.68% of the stock is owned by institutional investors.

Dyne Therapeutics News Summary

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: Lifesci Capital raised multiple quarterly and full‑year EPS forecasts and reiterated a “Strong‑Buy” rating, trimming FY2026 loss forecasts (improved EPS trajectory). This reduces modeled downside and supports valuation assumptions for a clinical‑stage biotech. Lifesci Capital raises estimates
• Positive Sentiment: Coverage/flow update — ClearBridge’s small‑cap growth fund added DYN in Q4, which can provide incremental buying pressure and credibility from a well‑known active manager. That can help near‑term liquidity and investor interest. ClearBridge small-cap growth trims Duolingo, Biohaven, QLYS; adds PTGX, SSD, BETA, DYN in Q4
• Positive Sentiment: Japan regulatory development: analysis on a recent Japanese orphan designation (or related nod) highlights potential market expansion and a clearer pathway for rare‑disease programs — a meaningful long‑term commercial and partnership positive if confirmed. How Does Japan’s Orphan Nod Shape Dyne Therapeutics’ (DYN) Global Rare-Disease Strategy?
• Negative Sentiment: JPMorgan reportedly lowered its expectations for DYN’s stock price — a negative signal that can weigh on sentiment and prompt short‑term selling or reduced conviction among some institutional holders. JPMorgan Chase & Co. Has Lowered Expectations for Dyne Therapeutics (NASDAQ:DYN) Stock Price

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.